Skip to content

Mescaline-induced behavioral alterations are mediated by 5-HT2A and 5-HT2C receptors in rats.

Lucie Olejníková-Ladislavová, Michaela Fujáková-Lipski, Klára Šíchová, Hynek Danda, Kateřina Syrová, Jiří Horáček, Tomáš Páleníček

Pharmacology, biochemistry, and behavior December 1, 2024 DOI: 10.1016/j.pbb.2024.173903 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Experimental study Peer reviewed
Population Adult male Wistar rats
Interventions Mescaline 5-HT2A antagonist 5-HT2C antagonist
Dose 10, 20, and 100 mg/kg
Topics Mescaline Serotonin
Keywords Psychedelics hallucinogens Locomotor activity Sensorimotor gating Psychedelic compounds Psychoactive substances Neuroscience brain chemistry Neurotransmitters Neural mechanisms Serotonin receptors 5-ht2a
Citations 5
Key findings Mescaline-induced hyperlocomotion and sensorimotor gating deficits in rats are primarily mediated by the 5-HT2A receptor subtype, with a lesser contribution from the 5-HT2C receptor.

Abstract

Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood. In this study, we aimed to investigate how selective antagonists of 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT1A receptors affect the behavioral changes induced by subcutaneous administration of mescaline (at doses of 10, 20, and 100 mg/kg) in rats. We used adult male Wistar rats in all our experiments. We evaluated locomotor activity using the open field test, and assessed sensorimotor gating deficits by measuring prepulse inhibition (PPI) of acoustic startle reaction (ASR). While the highest dose of mescaline induced hyperlocomotion (p < 0.001), which almost all the other antagonists reversed (p < 0.05-0.001), the PPI deficits were selectively normalized by the 5-HT2A antagonist (p < 0.05-0.01). The 5-HT2C antagonist partially reversed the small PPI deficit induced by lower doses of mescaline (p = 0.0017). Our findings suggest that mescaline-induced changes in behavior are primarily mediated by the 5-HT2A receptor subtype, with less pronounced contributions from the 5-HT2C receptor. The other antagonists had limited effects.

Explore topics